CYRX — Cryoport, Inc.

Cryoport (CYRX) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $47.8 million, a 16% increase year-over-year.
• Commercial Cell and Gene Therapy Revenue: Grew 26% to $9.1 million.
• Clinical Trials Revenue: Increased 18% to $12.9 million.
• Life Sciences Services Segment Revenue: Up 18% year-over-year, with BioStorage/BioServices growing 21%.
• Life Sciences Products Segment Revenue: Grew 15%, driven by demand for MVE Biological Solutions cryogenic systems.
• Adjusted EBITDA: Improved by $2.2 million year-over-year, nearing breakeven at a negative $0.6 million.
• Clinical Trials Supported: 766 global clinical trials, with 91 in Phase III.

2. Strategic Updates and Business Highlights:

• Cryoport continues to support a broad cell and gene therapy pipeline, with a record number of clinical trials.
• The company achieved a milestone with the first shipment of cryopreserved clinical trial materials from its IntegriCell facilities.
• A strategic partnership with DHL Group has shifted CRYOPDP's financials to discontinued operations.
• The introduction of the Fusion 800 series cryogenic freezer aims to open new markets.
• Ongoing digital initiatives include the use of generative AI to enhance operational efficiency.

3. Forward Guidance and Outlook:

• Full-year 2026 revenue guidance raised to $192 million to $196 million.
• Anticipation of positive adjusted EBITDA in the second half of 2026.
• Expected 10 BLA or MAA application filings and up to 8 new therapy approvals in 2026.

4. Bad News, Challenges, or Points of Concern:

• The company remains cautious due to global macroeconomic uncertainties, leading to a conservative revenue guidance increase despite a strong Q1 performance.
• The growth in clinical trials was only a net increase of 6, with 23 trials removed, although many were completed, indicating maturation rather than decline.
• Margins in the Life Sciences Products segment were lighter than expected, attributed to product mix rather than competitive pressures or pricing erosion.

5. Notable Q&A Insights:

• Management emphasized the importance of ongoing investments in facilities and AI initiatives to drive future growth and efficiency.
• There is optimism about the momentum in biotech funding and its potential impact on RFP volumes and contract activity.
• The growth in commercial cell and gene therapy revenue is expected to continue, but management indicated that the guidance is based on existing therapies rather than new approvals.
• The company is seeing strong demand across geographies for MVE products, with a projected high single-digit growth rate for the segment moving forward.

Overall, Cryoport's Q1 2026 results reflect strong growth and strategic positioning in the cell and gene therapy market, while also acknowledging the need for cautious optimism amid broader economic challenges.